Based on the expression characteristics of VEGF in melasma lesions, a hypothesis has been proposed to use vascular endothelial growth factor inhibitors in combination with anti-estrogenic drugs for topical administration in the treatment of melasma (Cohen, 2017). The gene discussed is VEGFA; the disease is freckles.